QNZ46

Research use only, not for human use.

QNZ46 is a NR2C/NR2D-selective NMDA receptor non-competitive antagonist.

QNZ46 is a NMDA receptor antagonist. QNZ46 inhibits NMDA receptor function in a noncompetitive and voltage-independent manner by an unconventional mechanism that requires binding of glutamate to the GluN2 subunit, but not glycine binding to the GluN1 subunit. QNZ46 could provide an opportunity for the development of pharmacological tools and therapeutic agents that target NMDA receptors at a new site and modulate function by a novel mechanism. NMDA receptors are ionotropic glutamate receptors that mediate excitatory synaptic transmission and have been implicated in several neurological diseases.

——

——

QNZ46 | QNZ-46 | QNZ 46

MAPK/ERK Signaling

MEK

NR2A| NR2C| NR2D

Neurological Disease

——

1237744-13-6

443.41

C24H17N3O6

>98% (HPLC)

DMSO : ≥ 4.5 mg/mL10.15 mM

COc1cc2c(cc1)nc(n(c2=O)c1ccc(cc1)C(=O)O)/C=C/c1cc(ccc1)[N+](=O)[O-]

(E)-4-(6-methoxy-2-(3-nitrostyryl)-4-oxoquinazolin-3(4H)-yl)benzoic acid

(-20℃)

With Ice Pack

≥ 2 years